Search in:

Advanced search

Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 11

Submit an article Journal homepage

Views

CrossRef citations to date

Altmetric

Reviews

Recombinant human thyrotropin in the management of thyroid disorders

Gilberto J Paz-Filho SEMPR – Serviço de Endocrinologia e Metabologia da UFPR, Curitiba, Brazil, 1756 N Bayshore Dr, apt 11J, Miami, FL 33132, USA +1 305 243 2128; +1 305 243 9708; [email protected]

, MD &

Hans Graf SEMPR – Serviço de Endocrinologia e Metabologia da UFPR, Curitiba, Brazil, 1756 N Bayshore Dr, apt 11J, Miami, FL 33132, USA +1 305 243 2128; +1 305 243 9708; [email protected]

, MD PhD

Pages 1721-1732 | Published online: 10 Oct 2008

Cite this article
https://doi.org/10.1517/14712598.8.11.1721

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Cole ES, Lee K, Lauziere K, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (NY) 1993;11:1014-24
PubMedGoogle Scholar
Grossmann M, Weintraub BD, Szkudlinski MW. Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Endocr Rev 1997;18:476-501
PubMed Web of Science ®Google Scholar
Szkudlinski MW, Thotakura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993;133:1490-503
PubMed Web of Science ®Google Scholar
Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:5148-51
PubMed Web of Science ®Google Scholar
Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31
PubMed Web of Science ®Google Scholar
Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004;351:1764-71
PubMed Web of Science ®Google Scholar
American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society; 2008
Google Scholar
Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42
PubMed Web of Science ®Google Scholar
Maia AL, Ward LS, Carvalho GA, et al. [Thyroid nodules and differentiated thyroid cancer: Brazilian consensus]. Arq Bras Endocrinol Metabol 2007;51:867-93
PubMed Web of Science ®Google Scholar
Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803
PubMed Web of Science ®Google Scholar
Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76
PubMed Web of Science ®Google Scholar
Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-9
PubMed Web of Science ®Google Scholar
Luster M, Felbinger R, Dietlein M, et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005;15:1147-55
PubMed Web of Science ®Google Scholar
Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11:865-9
PubMed Web of Science ®Google Scholar
Berg G, Lindstedt G, Suurkula M, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002;25:44-52
PubMed Web of Science ®Google Scholar
Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-8
PubMed Web of Science ®Google Scholar
Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-5
PubMed Web of Science ®Google Scholar
Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 2006;27:627-32
PubMed Web of Science ®Google Scholar
Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32
PubMed Web of Science ®Google Scholar
Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54
PubMed Web of Science ®Google Scholar
Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6
PubMed Web of Science ®Google Scholar
Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84
PubMed Web of Science ®Google Scholar
Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-70
PubMed Web of Science ®Google Scholar
Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61-74
PubMed Web of Science ®Google Scholar
Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008;93:76-81
PubMed Web of Science ®Google Scholar
Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002;9:227-47
PubMed Web of Science ®Google Scholar
Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5
PubMed Web of Science ®Google Scholar
Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7
PubMed Web of Science ®Google Scholar
Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-7
PubMed Web of Science ®Google Scholar
Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73
PubMed Web of Science ®Google Scholar
Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85
PubMed Web of Science ®Google Scholar
Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41
PubMed Web of Science ®Google Scholar
Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12
PubMed Web of Science ®Google Scholar
Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 2003;30:1077-86
PubMed Web of Science ®Google Scholar
Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001;144:5-11
PubMed Web of Science ®Google Scholar
Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16:1121-30
PubMed Web of Science ®Google Scholar
Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005;12:49-64
PubMed Web of Science ®Google Scholar
Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999;84:3636-41
PubMed Web of Science ®Google Scholar
Wesche MF, Tiel-v-Buul MM, Smits NJ, et al. Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter. Eur J Endocrinol 1995;132:86-7
PubMed Web of Science ®Google Scholar
Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease. N Engl J Med 1998;338:1438-47
PubMed Web of Science ®Google Scholar
Hegedus L, Hansen BM, Knudsen N, et al. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ 1988;297:661-2
PubMed Web of Science ®Google Scholar
Nygaard B, Faber J, Hegedus L, et al. 131I treatment of nodular non-toxic goitre. Eur J Endocrinol 1996;134:15-20
PubMed Web of Science ®Google Scholar
Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000;85:3592-6
PubMed Web of Science ®Google Scholar
Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001;86:5330-6
PubMed Web of Science ®Google Scholar
Diehl LA, Romaldini JH, Graf H, et al. Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. Clin Endocrinol (Oxf) 2006;65:433-8
PubMed Web of Science ®Google Scholar
Lawrence JE, Emerson CH, Sullaway SL, et al. The effect of recombinant human TSH on the thyroid (123)I uptake in iodide treated normal subjects. J Clin Endocrinol Metab 2001;86:437-40
PubMed Web of Science ®Google Scholar
Nieuwlaat WA, Huysmans DA, Van Den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003;88:3121-9
PubMed Web of Science ®Google Scholar
Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract 2003;9:204-9
PubMedGoogle Scholar
Duick DS, Baskin HJ. Significance of radioiodine uptake at 72 hours versus 24 hours after pretreatment with recombinant human thyrotropin for enhancement of radioiodine therapy in patients with symptomatic nontoxic or toxic multinodular goiter. Endocr Pract 2004;10:253-60
PubMedGoogle Scholar
Cohen O, Ilany J, Hoffman C, et al. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 2006;154:243-52
PubMed Web of Science ®Google Scholar
Albino CC, Mesa CO Jr, Olandoski M, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005;90:2775-80
PubMed Web of Science ®Google Scholar
Paz-Filho GJ, Mesa-Junior CO, Olandoski M, et al. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res 2007;40:1661-70
PubMed Web of Science ®Google Scholar
Paz-Filho G, Mesa C, Carvalho G, et al. Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after two years. Clin Endocrinol (Oxf) 2007;69:345-6
PubMed Web of Science ®Google Scholar
Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 2004;60:300-8
PubMed Web of Science ®Google Scholar
Nielsen VE, Bonnema SJ, Boel-Jorgensen H, et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006;166:1476-82
PubMed Web of Science ®Google Scholar
Bonnema SJ, Nielsen VE, Boel-Jorgensen H, et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007;92:3424-8
PubMed Web of Science ®Google Scholar
Medeiros-Neto G, Marui S, Knobel M. An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine 2008;33:109-17
PubMed Web of Science ®Google Scholar
Fugazzola L, Persani L, Mannavola D, et al. Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement. Clin Endocrinol (Oxf) 2003;59:230-6
PubMed Web of Science ®Google Scholar
Tiosano D, Even L, Shen Orr Z, et al. Recombinant thyrotropin in the diagnosis of congenital hypothyroidism. J Clin Endocrinol Metab 2007;92:1434-7
PubMed Web of Science ®Google Scholar
Filipsson H, Nystrom E, Johannsson G. Exploring the use of recombinant human thyrotropin in the diagnosis of central hypothyroidism. Eur J Endocrinol 2008;159:153-60
PubMed Web of Science ®Google Scholar
Albino C, Paz-Filho G, Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis. Clin Endocrinol 2008 [Epub ahead of print]
Google Scholar
Borget I, Corone C, Nocaudie M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007;156:531-8
PubMed Web of Science ®Google Scholar
Mernagh P, Campbell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006;155:405-14
PubMed Web of Science ®Google Scholar
Barbaro D, Boni G. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when. Eur J Surg Oncol 2007;33:535-40
PubMed Web of Science ®Google Scholar
Potzi C, Moameni A, Karanikas G, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 2006;65:519-23
PubMed Web of Science ®Google Scholar
Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid 2008;18:509-16
PubMed Web of Science ®Google Scholar
Norden MM, Larsson F, Tedelind S, et al. Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res 2007;67:7512-7
PubMed Web of Science ®Google Scholar
Silberstein EB. Comparison of outcomes after 123;I versus 131;I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 2007;48:1043-6
PubMed Web of Science ®Google Scholar
Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7
PubMed Web of Science ®Google Scholar
Zophel K, Wunderlich G, Kotzerke J. A highly sensitive thyroglobulin assay has superior diagnostic sensitivity for recurrence of differentiated thyroid cancer in patients undergoing TSH suppression. J Nucl Med 2006;47:552-3; author reply 3
PubMed Web of Science ®Google Scholar
Barca MF, Gruppi C, Oliveira MT, et al. Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH. Endocrine 2007;32:175-81
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Recombinant human thyrotropin in the management of thyroid disorders

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Recombinant human thyrotropin in the management of thyroid disorders

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date